Belite Bio Inc reports results for the quarter ended December 31 - Earnings Summary

• Belite Bio Inc BLTE.OQ reported a quarterly adjusted loss of 70 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -32 cents. The mean expectation of eight analysts for the quarter was for a loss of 55 cents per share. Wall Street expected results to range from -66 cents to -43 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Belite Bio Inc's reported EPS for the quarter was a loss of 70 cents​.

• The company reported a quarterly loss of $25.32 million.

• Belite Bio Inc shares had risen by 19.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Belite Bio Inc is $193.00, about 1.4% above its last closing price of $190.30

This summary was machine generated from LSEG data March 2 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)